Kembi Therapeutics

Kembi Therapeutics Pty Ltd supports the development and clinical testing of seviteronel, a small molecule drug that blocks androgen signaling to prevent aggressive adaptation in triple negative breast cancer. In preclinical studies, combining seviteronel with chemotherapy doubled tumor reduction compared to chemotherapy alone. The company sponsors/supports an ongoing investigator-led clinical trial in Australia targeting metastatic TNBC patients who have limited treatment options. Seviteronel was originally developed for hormone-driven cancers but has shown promise as an adjunct therapy to sensitize tumors to chemotherapy by inhibiting cell state switching.